Clinical Trial Update: A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b/Phase 2 single-arm trial evaluating golidocitinib in combination with an anti-PD-1 agent for previously treated non-small cell lung cancer; the study s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anti-PD-1 therapy
• Golidocitinib (golidocitinib)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Lung Cancer, Non-Small Cell | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING